Status and phase
Conditions
Treatments
About
To evaluate the bioequivalence of HS627(2 specifications) with PERJETA in a single intravenous administration in healthy subjects
Full description
This is a randomized, double-blind, parallel controlled,single-dose phase I study to compare the pharmacokinetics and safety of HS627 (2 specifications) with PERJETA in Chinese healthy male adults
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
180 participants in 3 patient groups
Loading...
Central trial contact
Yu Cao, Dr.Pharm; Liang Lin, Bachelor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal